Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

hibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in multiple myeloma as monotherapy, in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements relating to the potential for Kosan to receive milestone payments and royalties from the license agreement with Pfizer; the further development and potential safety, efficacy and commercialization of Kosan's product candidates, including without limitation PF-04548023 and other compounds from Kosan's motilin agonist program; and development plans with respect to PF-04548023 and the timing thereof. There are a number of
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Regulatory Affairs for Support Staff (London, ... offering. This two day course provides ... of drug development and has been designed specifically for ... You will gain an overview of EU regulatory ...
(Date:9/1/2015)... , Sept. 1, 2015 Egalet Corporation ... specialty pharmaceutical company focused on discovering, developing, and ... will be  presenting scientific data on SPRIX ® ... extended-release, oral morphine product candidate, and Egalet-002, an ... PainWeek 2015 to be held September ...
(Date:9/1/2015)... 1, 2015  Abbott (NYSE: ABT ) announced today ... randomized trial comparing the safety and effectiveness of Abbott,s ... , Abbott,s market-leading, permanent drug eluting stent. The trial ... and enrolled 400 people with coronary artery ... results will be featured at a late-breaking session today ...
Breaking Medicine Technology:Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 3Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 4Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 5Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 6Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4
... InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the ... that it has been approved by FINRA to have its ... symbol "NSPR". In addition, on March 31, 2011, ... it raised approximately $9.0 million of cash and (ii) approximately ...
... ATLANTA, May 5, 2011 CardioMEMS, Inc ., ... is commercializing a proprietary wireless sensing and communication technology ... and CEO Jay Yadav, M.D., has been chosen as ... Awards. The awards are presented by the Atlanta Business ...
Cached Medicine Technology:InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 2InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 3InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 4InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 5CardioMEMS Founder Dr. Jay Yadav Chosen as Health-Care Heroes Finalist by Atlanta Business Chronicle 2
(Date:9/1/2015)... ... September 01, 2015 , ... An ... of thousands of plastic surgeries conducted each year on teenagers, quoting a New ... growing numbers. Beverly Hills-based plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... explained how many dental practices across the country are switching from traditional dental ... to Beverly Hills cosmetic dentist Dr. Sam Saleh of Ora Dentistry Spa, his ...
(Date:9/1/2015)... ... September 01, 2015 , ... Earth Brands, ( http://www.earthbrands.com ) ... Every customer who buys an Earth Brand shoe will be given an opportunity ... for the Future, a nonprofit dedicated to planting more trees. Earth Brands products ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... it Red for Lymphoma awareness initiative, the nation’s premier and most high-profile lymphoma ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary ... teenagers, from ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College ... adult counselors, some of whom work for Calvary, and two junior counselors who were ...
Breaking Medicine News(10 mins):Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2Health News:Article on CAD/CAM Dental Technology Highlights the Advantages of 21st Century Dentistry, Notes Ora Dentistry Spa 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3
... Compounded Hormones, WASHINGTON, Feb. 12 ... called on the American,Association of Clinical Endocrinologists ... to fully disclose their financial ties to ... that directly benefits,the pharmaceutical giant. In recent ...
... 12 TeamStaff, Inc.,(Nasdaq: TSTF ) ... services, announced today that it is changing ... Staffing Services, Inc., to TeamStaff,Government Solutions (dba ... subsidiary currently provides medical, office,administration and logistics ...
... families may have underlying speech deficits , , TUESDAY, ... or family history of learning disabilities may be more ... causes them to lose language abilities as they age, ... known as primary progressive aphasia, causes language abilities to ...
... YUCAIPA, Calif., Feb. 12 Ingen Technologies,Inc. (OTC ... the signed distribution agreement with Progressive International,Holding Co. ... Taiwan, People,s,Republic of China, Japan and Korea. Please ... Progressive International Holding Company (PIHK),( http://www.pgiholding.com ) and ...
... announcement by,the United States Food and Drug Administration that ... toxin type A), customers are,looking for alternatives to treat ... in 2002 for the temporary treatment of,moderate to severe ... 65 years,of age. In its recent communication, the FDA ...
... Feb. 12 Iomai Corporation,(Nasdaq: IOMI ) today ... the second dose of the two-dose regimen for its ... when,self-applied by subjects outside of a clinical setting., ... program for the,vaccine, measured the immune response to the ...
Cached Medicine News:Health News:American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:Learning Disabilities May Presage Later Language Problems 2Health News:Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor 2Health News:Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor 3Health News:Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles 2Health News:Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch 2Health News:Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch 3Health News:Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: